Surgical resection of tumor

PROCEDURE3 trials

Sponsors

Jair Bar, M.D., Ph.D., Apexigen America, Inc., John Yu

Conditions

Central Nervous System TumorEsophageal CancerGastroEsophageal CancerNon Small Cell Lung CarcinomaStage IStage II

Phase 1

Anti PD-1 Neo-adjuvant Treatment for NSCLC

CompletedNCT02938624

Jair Bar, M.D., Ph.D.Non Small Cell Lung Carcinoma, Stage I, Stage II

Start: 2017-01-07End: 2021-08-31Updated: 2021-12-14

Phase 2

APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

CompletedNCT03165994

Apexigen America, Inc.Esophageal Cancer, GastroEsophageal Cancer

Start: 2017-10-06End: 2023-02-21Updated: 2024-05-02

Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System

CompletedNCT04743310

John YuCentral Nervous System Tumor

Start: 2021-09-30End: 2025-03-06Updated: 2025-06-13

Related Papers

A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers

Cancer Research Communications2025-02-014 citations

1361 Neoadjuvant CD40 agonism remodels the tumor immune microenvironment in locally advanced esophageal/gastroesophageal junction cancer

Regular and Young Investigator Award Abstracts2023-10-31

[Application of Neoadjuvant Immuno-chemotherapy in NSCLC].

2021-04-015 citations

Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Updated report of a phase I study, MK3475-223.

Journal of Clinical Oncology2019-05-2040 citations

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.

2019-05-0256 citations